ELAB

Company Overview — What Does PMGC Holdings Inc. Do?

We are a physician-dispensed skincare company with a focus on modernizing aesthetic skincare. We conduct research and development to advance innovative and science-driven topical skincare that complements the medical aesthetics industry. Upon our founding in 2020, we initiated our research and development phase for our current product formulations. Since 2022, we have principally employed a business-to-business model in which we produce and commercialize a new generation of topical skincare products that contain our proprietary stem cell-derived Elevai Exosomes™ designed to enhance the appearance of skin. Our exosome manufacturing process from source to skin is known as ‘Precision Regenerative Exosome Technology™’ or ‘PREx™’. PREx™ utilizes advanced patent-pending stem cell processing technology as part of our cohesive production process involving carefully controlled stem cell culture to produce stem cell derived factors that are featured in our topical exosome products. Specifically, as referenced herein “exosomes” are small membrane-bound vesicles that are released by cells that are involved in intercellular communication. They contain various types of biomolecules such as proteins, lipids, and nucleic acids, which can be transferred between cells and may modulate and support these natural cellular processes. Our proprietary PREx™ biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (“hUMSC”) for our specialty physician-dispensed skincare products. hUMSC are adult stem cells that can differentiate into various cell types. hUMSCs can be isolated from the Wharton’s Jelly portion of the umbilical cord and have shown therapeutic potential in various diseases such as osteoarthritis, myocardial infarction, and neurodegenerative diseases. Our products are comprised of topical cosmetic solutions to enhance the appearance of skin. Our products are not drug products or considered regenerative medicine, nor have any of our products received FDA approval. Our cosmetic products are not intended to prevent, treat or cure diseases or medical conditions. Moreover, our cosmetic products are not intended to be injected or delivered intravenously. Instead, our exosome-infused skincare products are topically applied to the skin to aid in the reduction of the appearance of a range of the most common cosmetic skin conditions, including the appearance of skin firmness, oxidative stress, photodamage, hyperpigmentation, and texture of soft tissue deficits, such as reducing the appearance of fine lines and wrinkles. Elevai Labs, Inc. was incorporated in Delaware in June 2020 under the original name Reactive Medical Labs Inc. Upon completion of the stock transfer agreement, Reactive Medical Inc. became our wholly owned subsidiary. In September 2022, Reactive Medical Inc. changed its name to Elevai Research Inc. Our principal executive offices are located at 120 Newport Center Dr. #250, Newport Beach, CA 92660. As of the date of this prospectus, we are qualified to do business as a foreign corporation in the state of California. PMGC Holdings Inc. (ELAB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jordan R. Plews. With a market capitalization of $8M, ELAB is one of the notable companies in the Healthcare sector.

PMGC Holdings Inc. (ELAB) Stock Rating — Reduce (April 2026)

As of April 2026, PMGC Holdings Inc. receives a Reduce rating with a composite score of 27.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ELAB ranks #2,614 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PMGC Holdings Inc. ranks #342 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ELAB Stock Price and 52-Week Range

PMGC Holdings Inc. (ELAB) currently trades at $4.63. The stock lost $0.63 (12.0%) in the most recent trading session. The 52-week high for ELAB is $11.13, which means the stock is currently trading -58.4% from its annual peak. The 52-week low is $1.01, putting the stock 358.4% above its annual trough. Recent trading volume was 5.4M shares, reflecting moderate market activity.

Is ELAB Overvalued or Undervalued? — Valuation Analysis

PMGC Holdings Inc. (ELAB) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.85x, versus the sector average of 2.75x. The price-to-sales ratio is 8.21x, compared to 1.66x for the average Healthcare stock.

At current multiples, PMGC Holdings Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PMGC Holdings Inc. Profitability — ROE, Margins, and Quality Score

PMGC Holdings Inc. (ELAB) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -80.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -48.7% versus the sector average of -33.1%.

On a margin basis, PMGC Holdings Inc. reports gross margins of 51.0%, compared to 71.5% for the sector. The operating margin is -471.7% (sector: -66.1%). Net profit margin stands at -595.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -52.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ELAB Debt, Balance Sheet, and Financial Health

PMGC Holdings Inc. has a debt-to-equity ratio of 64.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.74x, suggesting adequate working capital coverage. Total debt on the balance sheet is $3M. Cash and equivalents stand at $8M.

ELAB has a beta of 1.69, meaning it is more volatile than the broader market — a $10,000 investment in ELAB would be expected to move 68.5% more than the S&P 500 on any given day. The stability factor score for PMGC Holdings Inc. is 8/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PMGC Holdings Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, PMGC Holdings Inc. reported revenue of $813,426. Net income for the quarter was $-6M. Gross margin was 51.0%. Operating income came in at $-4M.

In FY 2025, PMGC Holdings Inc. reported revenue of $590,084. Net income for the quarter was $-8M. Gross margin was 31.4%. Operating income came in at $-6M.

In Q3 2025, PMGC Holdings Inc. reported revenue of $285,948. Net income for the quarter was $-3M. Gross margin was 27.3%. Revenue grew -45.8% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, PMGC Holdings Inc. reported revenue of $0. Net income for the quarter was $-562,355. Operating income came in at $-1M.

Over the past 8 quarters, PMGC Holdings Inc. has demonstrated a growth trajectory, with revenue expanding from $605,529 to $813,426. Investors analyzing ELAB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ELAB Dividend Yield and Income Analysis

PMGC Holdings Inc. (ELAB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ELAB Momentum and Technical Analysis Profile

PMGC Holdings Inc. (ELAB) has a momentum factor score of 40/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

ELAB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PMGC Holdings Inc. (ELAB) ranks #342 out of 838 stocks based on the Blank Capital composite score. This places ELAB in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ELAB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ELAB vs S&P 500 (SPY) comparison to assess how PMGC Holdings Inc. stacks up against the broader market across all factor dimensions.

ELAB Next Earnings Date

No upcoming earnings date has been announced for PMGC Holdings Inc. (ELAB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ELAB? — Investment Thesis Summary

The quantitative profile for PMGC Holdings Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. High volatility (stability score 8/100) increases portfolio risk.

In summary, PMGC Holdings Inc. (ELAB) earns a Reduce rating with a composite score of 27.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ELAB stock.

Related Resources for ELAB Investors

Explore more research and tools: ELAB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ELAB head-to-head with peers: ELAB vs AZN, ELAB vs SLGL, ELAB vs VMD.